UBS AM
BBH icon

UBS AM’s VanEck Biotech ETF BBH Stock Holding History

UBS AM’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$335K Sell
1,650
-66
-4% -$12.4K ﹤0.01% 2618
2026
Q1 		$323K Buy
1,716
+1,669
+3,551% +$322K ﹤0.01% 2645
2025
Q4 		$8.89K Buy
+47
New +$8.7K ﹤0.01% 2874

Other funds holding BBH

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CCA
Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

UBS AM's BBH Position: Q2 2026 in Review

UBS AM reduced its VanEck Biotech ETF (BBH) stake by 3.8% in Q2 2026, selling an estimated $12.4K and leaving 1,650 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #2618.

UBS AM first reported a position in BBH in Q4 2025 and has held it in 3 quarters since. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

  • UBS AM held 1,650 shares of VanEck Biotech ETF worth $335K as of Q2 2026.
  • UBS AM sold 66 VanEck Biotech ETF shares in Q2 2026, an estimated $12.4K.
  • VanEck Biotech ETF made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2618 holding.
  • UBS AM first reported a position in VanEck Biotech ETF in Q4 2025 and has held it in 3 quarters since.
  • 110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.